Importantly, while recent reports pointed to tumor-suppressive roles of desmoplasia and CAFs in PDAC [41–43], preclinical evidence also showed that the reduction of desmoplasia can improve accessibility to cancer cells and enhance antitumor response to cytotoxic chemotherapeutic agents [17, 44, 45], anti-VEGFR therapy [41], and immunotherapy [43, 46, 47]. The gene discussed is KDR; the disease is neoplasm.